sale trade et
sale trade et
share mil
per share per share dilut share basi
share mil share outstand basic
creat bluematrix
bring genet test mainstream medicin init
initi coverag buy rate pt
cost qualiti leader genet test market
central test data strategi believ posit
compani well compet larg attract market expect
strong top-line growth compani next three year base
market research channel check like manag
team abil execut confid sector go
place see invita growth leader among high-growth
digit health compani see stock mispric compar
valuat peer see potenti upsid name
next month manag execut stock trade
line valuat compar
like compani large-scal low-cost central test
model enabl compani offer wide rang genet test
servic across multipl diseas area note demand genet
test rise due broader accept provid
payer rapidly-fal cost test addit qualiti
depth data gener coupl lower price charg
make compani product attract provid posit
compani well market
see compani success partnership program signal
high commerci potenti compani test also
futur sourc growth compani partner
lice scienc includ alnylam pharmaceut buy
analyst keay naka acut hepat porphyria ahp hereditari
transthyretin hattr amyloidosi primari hyperoxaluria ph
unrat spinal muscular atrophi sma biomarin unrat
epilepsi gene panel test unrat
period paralysi test also exist partnership
blueprint medicin unrat ariad pharmaceut subsidiari
unrat takeda pharmaceut pharmaceut unrat
unrat parion scienc privat
see opportun addit upsid
industry-lead infrastructur wide array genet test servic
dynam busi model adopt chang technolog
space strong partnership program futur commerci potenti
larg repositori genom data see continu
differenti favor genet test space
pleas refer import disclosur inform regul analyst certif found page report
leader offer wide rang servic multipl clinic area increasingli accept
understand individu genet import make inform decis healthcar manag invita
offer genet test servic multipl clinic area well-posit capabl provid servic
increas demand genet inform space like continu expand genet
test market project increas owe rise demand person medicin well technolog
advanc space
compani provid unparallel deep high qualiti data afford cost indic abl
provid comprehens genotyp phenotyp data lower price competitor make invita
attract individu partner alik
multipl partner space like continu contribut compani bottom line
compani multipl partner variou sector includ biopharma research advocaci provid group
instanc offer biopharma-sponsor genet test certain individu
pt see high-growth genomic-test digit health compani believ
trade enterprise/revenu basi rel peer group high-growth digit health enterpris softwar
compani compani current trade revenu growth categori leader
compound-annual-growth-rate see compani under-valued rel valuat peer multipl
basi control growth compani valuat peer trade averag revenu control
growth see valuat multipl expand next month good execut get us
price
basket high-growth digit health softwar valuat compar includ neutral
risk achiev target price
govern regul govern regul may chang time could affect genet test
servic addit stringent regulatori privaci standard protect person health inform
need adher data breach and/or unauthor data access could detriment compani
technolog competit risk genet test accomplish use rapidli chang technolog test
interpret use base increas scientif inform gene genet network
compani success reli abil remain competit inform technolog platform includ
bioinformat analyt well databas subject unforeseen failur could affect way compani
perform busi addit current futur partner could choos use compani provid similar
servic genet test peer includ privat ambri genet konica minolta
genom privat connect tissu gene test privat coopergenom subsidiari coopersurg
unit cooper compani unrat genedx compani unrat mng laboratori privat
myriad genet unrat unrat preventiongenet privat quest diagnost unrat
reimburs risk healthcar payor may provid coverag genet test servic
addit may need invest signific resourc compli payor differ potenti
complex reimburs procedur and/or may experi delay relat reimburs risk could harm
compani oper
financi risk may need rais addit capit fund oper includ issu equiti
reach profit could potenti result share dilut sharehold
page
stock price volatil share price volatil common development compani biotechnolog sector
expos space servic busi partner
digit health compani provid genet test interpret test result compani test
panel packag includ gene implic multipl diseas area hereditari cardiovascular diseas
dermatolog diseas metabol disord neurolog condit development disord other provid
servic patient healthcar provid biopharma partner advocaci provid group
strongbridg biopharma unrat blueprint medicin unrat ariad pharmaceut subsidiari unrat
takeda pharmaceut unrat pharmaceut unrat unrat parion scienc
privat incorpor headquart san francisco california
page
corp offer rang comprehens high-qual afford molecular genet test servic
servic cover multipl clinic area cardiolog hereditari cancer metabol disord neurolog pediatr rare
diseas compani acquir multipl asset line manag strategi expand servic
nvta total revenu grew exponenti yoy reach revenu
surg primarili driven growth billabl test improv
averag revenu per test compani gener total revenu genet test report
deliveri servic remain genom network subscript servic
acquir four busi expand suit genom manag offer acquisit enabl
compani launch prenat perinat genet test servic januari acquir altavoic formerli
patientcrossroad altavoic patient-cent data compani offer global platform collect curat coordin
deliv inform patient clinician june complet acquisit ommdom inc end-
to-end platform cancergen connect platform help collect manag histor genet inform patient
diagnost compani provid carrier screen preimplant hereditari disord soon novemb
compani acquir combimatrix corpor specialist prenat diagnosi miscarriag analysi pediatr
incorpor state delawar januari locu develop inc compani
renam invita corpor stock current list new york stock exchang nyse februari
issu initi public offer share common stock issu price gross
proce
revenu billabl test volum
figur revenu billabl test volum
page
mn yoy growthrevenu mn revenu yoy test volum test volum invita corpor
product servic
offer number genet test servic high flexibl option custom compani
classifi servic follow broad categori
offer wide rang diagnost test servic across variou clinic area figur cardiolog
rare diseas porphyria compani offer singl price singl specimen within clinic area
instanc clinician choos pre-cur test combin multipl test custom test differ patient
expand spectrum clinic test servic includ assay total gene
servic could use proactiv health well screen
clinic area cover genet test
figur clinic area cover genet test
offer reproduct health test servic carrier screen preimplant embryo test prenat
diagnosi miscarriag analysi compani acquir servic two major acquisit start
genet inc combimatrix corp acquir august start genet inc modular diagnost compani
offer carrier screen preimplant embryo test test provid insight action inform
physician patient women partner order arriv correct diagnosi prescrib right therapi
combimatrix corp acquir novemb provid prenat diagnosi miscarriag analysi pediatr
page
clinic areasdiseas disorderscardiolog neurologyaortopathyand connect tissu disord arrhythmia arrhythmia cardiomyopathi cardiomyopathi cardiomyopathi skelet muscl diseas charcot-marie-tooth diseas congenit heart diseas congenit myasthen syndrom famili hypercholesterolemia hereditari sensori autonom neuropathi hereditari spastic paraplegia malign hyperthermia suscept motor neuropathi movement disord muscular dystrophi myopathi neuromuscular disord neuropathi relat disord pulmonari hypertens riboflavin transport defici neuronopathyhereditari cancerbreast cancerbreast gynecolog cancerscolorect gastrointestin cancerscross cancer panelsindividu hereditari cancer conditionsoth organ systemsstat turnaround timebon marrow failur syndromesdermatology-rel cancer syndromespediatr oncologynon-malign hematologyhereditari hemochromatosi hereditari thrombophiliametabol newbornscreen immunologyaminoacidopathiescarbohydr disorderscongenit disord glycosylationcreatin biosynthesi disorderscyst fibrosisfatti acid oxid defectsimmunologylysosom storag disordersmetabol disord sever combin immunodeficiencymet transport disordersorgan acidemiaspanel analyteurea cycl disorderspediatr diseaseciliopathiescongenit heart diseasecyst fibrosi chronic pancreatitisdevelopment disordersdisord sex development/endocrinologyepilepsi seizur development brain abnormalitiesey disordersovergrowth syndromesrasopathi noonan spectrum disord skelet disordersskin disordersporphyriasacut hepat porphyria invita corpor
development disord acquisit ad carrier screen preimplant embryo test
servic hereditari disord portfolio
offer proactiv genet test servic healthi adult interest learn potenti impact
genet structur health futur compani offer three test solut invita cancer screen ii
invita cardio screen iii invita genet health screen analyz gene respect
test patient understand risk develop hereditari cancer cardiovascular condit disord
accord healthi adult risk disord
undiagnos genet disord healthi adult
figur undiagnos genet disord healthi adult
page
found healthi adult carri seriou health-rel genet posit result clinic signific variant well-known cardiovascular cancer risk gene addit medic import disord higher popul incid repres remin posit result invita corpor
accord manag total address market modern medic system billion peopl
global studi conduct global market insight suggest valu genet test market billion
expect increas compound-annual-growth-rate key factor expect drive growth
market increas demand person medicin technolog advanc genet test
diagnost test market hold highest market share billion total genet test market
diagnost test market expect grow exponenti next year driven increas applic genet
test across variou diseas area increas preval chronic diseas global addit increas
preval chromosom abnorm genet disord newborn expect boost growth prenat
newborn test segment futur
page
testingcarri testingprenat new born testingdiagnost testingpharmacogenom testingothersu genet test market test type invita corpor
global genet test market wit rapid growth sinc incept human genom map april
march genet test unit gtu activ market clinic laboratori improv
amend clia -certifi laboratori us single-gen test compris major gtu test includ
multigen panel test whole exom sequenc test complex test product concert genet
track net new gtu enter market sinc net new gtu defin total number gtu
enter market minu gtu remov retir unavail rate gtu enter
market per day grow year averag test ad per day figur
net new addit gtu market stood believ addit would lead increas
avenu revenu gener
net new gtu introduc market distribut across variou clinic domain per studi
conduct concert genet pediatr rare diseas prenat hereditari cancer contribut net new
gtu introduc
classif net new gtu
page
figur classif net new gtu
mix reimburs landscap reimburs genet test
map human genom creat new opportun test genet product predict prevent treat diseas
genet test help assess diseas risk guid physician provid prevent measur test also predict drug
respons toxic
landscap reimburs genet test evolv code
genet test number code continu grow due lack standard bill procedur mani
test payers/incurr provid face challeng identifi test decid whether medic
appropri reimburs
competit compet compani offer molecular genet test servic compani specialti
refer laboratori offer convent single- multi-gen test primarili compet firm
myriad genet inc natera inc preventiongenet llc quest diagnost incorpor progen inc
compani also compet commerci academ laboratori provid similar molecular genet test servic
moreov manag expect market remain competit owe presenc establish and/or emerg
healthcar inform technolog servic compani may plan commerci product includ
informat analysi integr genet tool servic health well
page
dr sean georg current serv chief execut offic ceo focus promot usag
genet inform mainstream medicin prior posit presid chief oper offic
compani dr georg co-found locu develop early-stag genet analysi start-up
later acquir prior co-found locu serv variou leadership posit navigen
svp market svp life scienc busi affymetrix vice-president label detect busi
invitrogen dr georg also work mckinsey co molecular probe hold phd molecular genet
uc santa cruz ms molecular biolog uc santa barbara bs molecular genet ucla
shelli guyer veteran extens experi senior execut build lead financi team back
strong experi financi domain invest banker ventur capitalist current hold posit
chief offic cfo prior join ms guyer cfo veracyt inc unrat
also serv cfo evp financ administr irhythm technolog buy inc ms guyer
start career hambrecht quist later join jp morgan secur held variou key
posit includ princip healthcar bank west coast hold mba haa school
busi univers california ab princeton univers
bendekgey serv overse compani oper prior posit
compani cfo year mr bendekgey led financ administr oper function variou
public privat biotechnolog genom compani includ unrat nuvelo dnanexu hold
law degre stanford law school ba degre kalamazoo colleg
dr robert nussbaum current hold posit chief medic offic join august
dr nussbaum work serv variou leadership posit cancer genet prevent
program cardiovascular genet program april august activ member
ucsf institut human genet prior join institut chief genet diseas research branch
nation genom research institut dr nussbaum studi md harvard medic
school harvard-mit joint program health scienc technolog bachelor scienc appli
mathemat harvard colleg
katherin stueland serv chief commerci offic ntva manag variou initi sale
market pharma/biotech collabor investor relat public relat prior join work
variou public privat biotech compani includ dendreon corpor presid
commun investor relat ms stueland also work unrat joint ventur
takeda unrat abbott unrat
page
deriv revenu primarili reimburs genet test see compani achiev revenu
in-lin street consensu see compani achiev revenu approxim
also line street consensu see compani gross margin scale time
also line street consensu see test remain overwhelm
sourc revenu compani period compani adj ebitda loss see
compani remain adj ebitda neg futur loss
favor valuat characterist see high-growth next-gener diagnostic-test digit
health compani build genom data platform give compani competit advantag compani
favor valuat characterist includ leader genom test market believ larg
billon address market compani class-lead growth characterist compar high-growth digit
health compani expect grow top-line compound-annual-growth-rate next year accord estim
compani moder gross margin see rapidli improv
compani current trade revenu revenu compani valuat compar trade
revenu control revenu growth good execut see compani valuat multipl
expand revenu next month
page
page
forward revenue mcap averagepric lt epsshrt adj companytkcagr price hi lo rat ratingtarg upsid grow high growth digit health enterpris softwar valuat nacastlight nacornerston dario nanananaevol nanananairhythm technolog medidata solut model payloc hold tabula rasa nanananaultim veeva workday inc class median- cover compani believ trade enterpris valu revenu basislatest price sourc price oper stat street consensu factset stock ticker nm meaning na avail ltm last twelv month ev enterpris valu adj ebitda adjust ebitda margin total address market basi three year except year avail sourc total address ket compani document avail basi latest share price forward ep ebitdaev/revenuefactset street consensusev/gin corpor
appendix incom statement ccm estim
page
corp consolid incom statement growth expensescost gross total oper loss incom expens incom taxes- net profit/ loss per common share profit/ loss per common share share outstand chardan capit corpor
appendix balanc sheet ccm estim
page
corp consolid balanc sheet thousand yeyeyeyeyeyeyeassetscurr assetscash cash market account receivable- prepaid expens current total current non-curr assetsproperti equip restrict market secur non-current- intang asset net- goodwill- total non-curr total liabilitiescurr liabilitiesaccount accru capit leas oblig current debt current total current capit leas oblig net current debt net current long-term liabil relat earli exercis stock options- total convert prefer stockpref stock- common accumul comprehens addit paid-in accumul total stockhold equiti corpor
